SUPN - ス―パ―ナス・ファ―マス―ティカルズ (Supernus Pharmaceuticals Inc.) ス―パ―ナス・ファ―マス―ティカルズ

 SUPNのチャート


 SUPNの企業情報

symbol SUPN
会社名 Supernus Pharmaceuticals Inc (ス―パ―ナス・ファ―マス―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 スパーナス・ファーマシューティカルズ(Supernus Pharmaceuticals Inc.)は中枢神経系疾患の治療薬の開発と商品化を中心とする製薬会社である。同社はてんかん患者のための2つの治療法であるOxtellar XR(拡張放出oxcarbazepine)とTrokendi XR(拡張放出トピラメート)を提供する。また、アンメットメディカルニーズに対処するための精神医学における複数の製品候補を開発し、衝動性衝動(IA)の治療および注意欠陥多動性障害(ADHD)の治療の市場機会を開発する。ADHD患者でIAを治療するために、SPN-810(塩酸モリンドン)を開発中である。ADHD患者の治療薬候補として、SPN-812(塩酸ビロキサジン)を開発中である。同社の神経系のポートフォリオは、オクテラールXRとトロケンディXRで構成される。これらは、米国市場でてんかん治療薬であるオキサカルバゼピンおよびトピラメートの最初の製品である。   ス―パ―ナス・ファ―マス―ティカルズは米国の製薬会社。中枢神経系疾患の治療薬の開発、商品化を行う。てんかん治療薬「オックステラ―ルXR(一般名オクスカルバセチン)」と「トロケンディXR(トピラマ―ト)」を委託製造、販売。また、注意欠陥多動性障害、自閉症、躁うつ病の治療薬を開発中。   Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations ("on-off" episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.
本社所在地 1550 East Gude Drive Rockville MD 20850 USA
代表者氏名 Charles W. Newhall チャールズW.ニューホール
代表者役職名 Independent Chairman of the Board
電話番号 +1 301-838-2500
設立年月日 38412
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数 422人
url www.supernus.com
nasdaq_url https://www.nasdaq.com/symbol/supn
adr_tso
EBITDA EBITDA(百万ドル) 133.42000
終値(lastsale) 47
時価総額(marketcap) 2454073698
時価総額 時価総額(百万ドル) 2485.402
売上高 売上高(百万ドル) 358.80000
企業価値(EV) 企業価値(EV)(百万ドル) 2632.909
当期純利益 当期純利益(百万ドル) 96.40200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Supernus Pharmaceuticals Inc revenues increased 42% to $190M. Net income increased from $27.7M to $57.1M. Revenues reflect Net product sales increase of 44% to $186.2M Royalty revenue increase of 32% to $3.1M. Net income benefited from Interest income increase from $1.2M to $4.9M (income) Loss on extinguishment of debt decrease from $204K (expense) to $0K.

 SUPNのテクニカル分析


 SUPNのニュース

   Supernus Pharmaceuticals (SUPN) Set to Announce Earnings on Wednesday  2021/11/02 16:00:41 Dakota Financial News
Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to release its earnings data after the market closes on Wednesday, November 3rd. Analysts expect Supernus Pharmaceuticals to post earnings of $0.21 per share for the quarter. Supernus Pharmaceuticals has set its FY 2021 guidance at EPS.Persons interested in registering for the companys earnings conference call can do so using []
   SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, DSPG, ...  2021/11/01 13:00:50 Hosttech
(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 1, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash. If you are an Adamas shareholder, click here to learn more about your rights and options. DSP Group, Inc. (NASDAQ:DSPG) concerning potential violations of the federal securities laws and/or breaches ..
   ADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the Firm  2021/10/27 16:36:00 Intrado Digital Media
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors of its investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN).
   Supernus Pharmaceuticals Inc. (NASDAQ:SUPN): Buy, Sell Or Hold At $29.80?  2021/10/23 13:00:00 Marketing Sentinel
In last trading session, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) saw 0.3 million shares changing hands with its beta currently measuring 1.20. Companys recent per share price level of $29.80 trading at $0.42 or 1.43% at ring of the bell on the day assigns it a market valuation of $1.55B. That closing price of SUPNs stock is Supernus Pharmaceuticals Inc. (NASDAQ:SUPN): Buy, Sell Or Hold At $29.80? Read More »
   Zacks: Brokerages Expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Earnings of $0.21 Per Share  2021/10/22 19:50:41 Transcript Daily
Wall Street analysts forecast that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will announce earnings per share of $0.21 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Supernus Pharmaceuticals earnings, with the highest EPS estimate coming in at $0.26 and the lowest estimate coming in at $0.18. Supernus Pharmaceuticals posted earnings []
   Supernus Pharma appoints Opgen executive as new CFO  2021/07/30 15:49:20 Seeking Alpha
   Supernus Pharma inks supply agreement with Bachem for key ingredient in ADHD drug  2021/07/20 10:48:19 Seeking Alpha
   Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?  2021/06/17 13:31:00 Benzinga
NEW YORK , June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSR, TRCH, NTEC, SUPN, and CYTH. Full story available on Benzinga.com
   Apomorphine Hydrochloride Market Risk Factors, Economic Fluctuations, Drivers In Future Analysis By -2027|Supernus Pharmaceuticals, Britannia Pharmaceuticals STADA, Ever Pharma  2021/06/13 16:17:50 Jumbo News
The global Apomorphine Hydrochloride market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Apomorphine Hydrochloride market. The research study comes out as a compilation []
   Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure  2021/06/10 17:21:00 Investor''s Business Daily
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
   Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?  2021/06/17 13:31:00 Benzinga
NEW YORK , June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSR, TRCH, NTEC, SUPN, and CYTH. Full story available on Benzinga.com
   Apomorphine Hydrochloride Market Risk Factors, Economic Fluctuations, Drivers In Future Analysis By -2027|Supernus Pharmaceuticals, Britannia Pharmaceuticals STADA, Ever Pharma  2021/06/13 16:17:50 Jumbo News
The global Apomorphine Hydrochloride market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Apomorphine Hydrochloride market. The research study comes out as a compilation []
   Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure  2021/06/10 17:21:00 Investor''s Business Daily
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
   Analysts Top Healthcare Picks: Novavax (NVAX), Supernus Pharmaceuticals (SUPN)  2021/06/02 12:25:40 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX), Supernus Pharmaceuticals (SUPN) The post Analysts Top Healthcare Picks: Novavax (NVAX), Supernus Pharmaceuticals (SUPN) appeared first on Smarter Analyst .
   Aequus Pharmaceuticals bringing diverse pipeline of new drugs to the Canadian market  2021/05/28 21:00:00 Proactive Investors Canada
Focused on developing and commercializing high-quality products Pipeline includes several commercial products in ophthalmology and transplant Also has a development stage pipeline in neurology What Aequus Pharmaceuticals does Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) is a specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. The Vancouver-based company takes medications that are already available in the US or elsewhere and licenses or acquires the Canadian rights, then takes the clinical data that supported that approval and works with Health Canada, Canadas national health system, to get them approved and commercialized in Canada. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and looks to form strategic partnerships that would maximize the reach of its product candidates worldwide. The company has expanded its pipeline to include several commercial products in Opthalmology and transplant and also has a development stage pipeline in neurology with the goal of addressing a need for improved medication adherence through enhanced delivery systems.

 関連キーワード  (医薬品 米国株 ス―パ―ナス・ファ―マス―ティカルズ SUPN Supernus Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)